Stoke Therapeutics, Inc. (STOK) FY2026 Q2 P&L / Income Statement

Stoke Therapeutics, Inc. (STOK) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Collaborative Arrangement and Arrangement Other than Collaborative. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenue

9,325,000 US dollars

Total operating expenses

74,754,000 US dollars

(Loss) income from operations

negative 65,429,000 US dollars

Total other income (expense)

3,811,000 US dollars

(Loss) income before income taxes

negative 61,618,000 US dollars

Provision for income taxes

0 US dollars

Net (loss) income

negative 61,618,000 US dollars

Acadia Agreement

2,800,000 US dollars

Biogen License Agreement

6,500,000 US dollars

Undisclosed (calculated)

25,000 US dollars

Total operating expenses

74,754,000 US dollars

Chart connections

• Revenue minus operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.